Viewing nowCombinationLinaZetin Duo Tablet 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.

MFDS item code 201902756 · Approved 2019.04.29 · Insurance code 642906850
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood glucose control for patients with type 2 diabetes who are taking both linagliptin and metformin. When taken in conjunction with dietary and exercise therapy, it can effectively manage blood glucose levels. It is used to help significantly manage blood glucose control and improve diabetes symptoms.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, the insulin dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antidiabetic drugs to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that could increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).
This medication contains two components, metformin and linagliptin, and is primarily used for the treatment of type 2 diabetes. There is a risk of rare but serious side effects like lactic acidosis, so patients with poor kidney function, liver problems, acute heart disease, heart failure, or acute alcohol intoxication should not take this medication. Moreover, it should not be given to individuals with hypersensitivity to this medication or those with type 1 diabetes, diabetic ketoacidosis, or pre-coma conditions. When used with other antidiabetic medications or insulin that have a risk of hypoglycemia, patients should be cautious of hypoglycemic symptoms, and the dose of hypoglycemic drugs may need to be reduced if necessary. Elderly patients with impaired kidney function or those taking medications that may impact kidney function should have regular kidney function tests, and if kidney function is severely diminished, this medication should be discontinued. This medication should be temporarily stopped during acute illnesses or around the time of surgery, and also before and after administration of iodine-based contrast agents used in radiological examinations, while ensuring kidney function is assessed. During use, there may be rare skin conditions like acute pancreatitis or blistering dermatosis, so if persistent severe abdominal pain or blistering or rash occurs, patients should consult a doctor immediately. Long-term use may lead to vitamin B12 deficiency, so if there are signs of anemia or neurological symptoms, blood tests should be conducted to check vitamin B12 levels. Women who are pregnant or may become pregnant and nursing mothers are advised not to use this medication. Safety has not been established for children and adolescents, and its use is not recommended. Elderly patients are at risk for decreased kidney function, so caution is advised when administering, and regular kidney function tests are necessary. Taking this medication with alcohol may increase the risk of lactic acidosis, so alcohol consumption should be avoided. Additionally, there may be interactions with specific medications, so patients should inform their doctor or pharmacist of any other medications they are taking. In case of overdose, serious side effects like lactic acidosis may occur, and immediate hospital treatment should be sought, which may include hemodialysis. Store this medication away from the reach of children, avoiding moisture and keeping it in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a tightly sealed container. It is advisable to store it at room temperature, between 1 to 30 degrees Celsius. This will help maintain the medication's effectiveness and prevent degradation.
Bright orange, double convex, oval-shaped film-coated tablet
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.